DZ3239A1 - Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés - Google Patents

Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés

Info

Publication number
DZ3239A1
DZ3239A1 DZ013239A DZ013239A DZ3239A1 DZ 3239 A1 DZ3239 A1 DZ 3239A1 DZ 013239 A DZ013239 A DZ 013239A DZ 013239 A DZ013239 A DZ 013239A DZ 3239 A1 DZ3239 A1 DZ 3239A1
Authority
DZ
Algeria
Prior art keywords
dicarboxylates
diabetes
preparation
treatment
methods
Prior art date
Application number
DZ013239A
Other languages
English (en)
Inventor
Howard Yoshihisa Ando
Donald Eugene Butler
Gary Jay Dozeman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3239A1 publication Critical patent/DZ3239A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/305Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DZ013239A 2000-01-25 2001-01-11 Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés DZ3239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17782300P 2000-01-25 2000-01-25
PCT/IB2001/000026 WO2001055078A1 (fr) 2000-01-25 2001-01-11 Ethers de dicarboxylate de calcium, leurs procedes de fabrication et leur utilisation dans le traitement des maladies vasculaires et du diabete

Publications (1)

Publication Number Publication Date
DZ3239A1 true DZ3239A1 (fr) 2001-08-02

Family

ID=22650106

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013239A DZ3239A1 (fr) 2000-01-25 2001-01-11 Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés

Country Status (39)

Country Link
EP (1) EP1259474B1 (fr)
JP (1) JP4750995B2 (fr)
KR (1) KR20020073182A (fr)
CN (1) CN1395555A (fr)
AP (1) AP2002002587A0 (fr)
AR (1) AR029436A1 (fr)
AT (1) ATE431326T1 (fr)
AU (1) AU2214001A (fr)
BG (1) BG106851A (fr)
BR (1) BR0107763A (fr)
CA (1) CA2397960C (fr)
CO (1) CO5261537A1 (fr)
CZ (1) CZ20022474A3 (fr)
DE (1) DE60138686D1 (fr)
DK (1) DK1259474T3 (fr)
DZ (1) DZ3239A1 (fr)
EA (1) EA004862B1 (fr)
EE (1) EE200200404A (fr)
ES (1) ES2324281T3 (fr)
GE (1) GEP20053428B (fr)
GT (1) GT200100015A (fr)
HN (1) HN2001000011A (fr)
HU (1) HUP0204422A3 (fr)
IL (1) IL150541A0 (fr)
IS (1) IS6442A (fr)
MA (1) MA26867A1 (fr)
MX (1) MXPA02007223A (fr)
NO (1) NO20023526L (fr)
NZ (1) NZ519550A (fr)
OA (1) OA12166A (fr)
PA (1) PA8510601A1 (fr)
PE (1) PE20011064A1 (fr)
PL (1) PL357076A1 (fr)
SK (1) SK10622002A3 (fr)
SV (1) SV2002000290A (fr)
TN (1) TNSN01013A1 (fr)
UY (1) UY26550A1 (fr)
WO (1) WO2001055078A1 (fr)
ZA (1) ZA200205880B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481962A1 (fr) * 1997-12-12 2004-12-01 Warner-Lambert Company LLC Nouveau carboxyéthylether reduisant la cholesterolémie
AU2003255937A1 (en) * 2002-08-22 2004-03-11 Warner-Lambert Company Llc Method of treating osteoarthritis
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
JPWO2006115130A1 (ja) * 2005-04-19 2008-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビス[(2s)−3−[3−[(2s)−3−(4−クロロ−2−シアノフェノキシ)−2−フルオロプロポキシ]フェニル]−2−イソプロポキシプロピオン酸]カルシウム及びその中間体
SG10201912713YA (en) * 2014-11-14 2020-02-27 Gemphire Therapeutics Inc PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
CA3059073A1 (fr) 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, sels pharmaceutiquement acceptables de celui-ci, compositions de celui-ci et procedes d'utilisation de celui-ci
WO2020081837A1 (fr) * 2018-10-18 2020-04-23 Gemphire Therapeutics Inc. Gemcabène, sels pharmaceutiquement acceptables de celui-ci, compositions correspondantes et procédés d'utilisation associés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
CO5261537A1 (es) 2003-03-31
BR0107763A (pt) 2002-11-12
EE200200404A (et) 2003-10-15
CZ20022474A3 (cs) 2003-06-18
AR029436A1 (es) 2003-06-25
MA26867A1 (fr) 2004-12-20
AU2214001A (en) 2001-08-07
SK10622002A3 (sk) 2003-07-01
JP2003520835A (ja) 2003-07-08
NO20023526D0 (no) 2002-07-24
IS6442A (is) 2002-06-25
JP4750995B2 (ja) 2011-08-17
EA200200641A1 (ru) 2002-12-26
HN2001000011A (es) 2001-06-13
ZA200205880B (en) 2003-07-23
WO2001055078A1 (fr) 2001-08-02
TNSN01013A1 (fr) 2005-11-10
PE20011064A1 (es) 2001-10-22
EP1259474A1 (fr) 2002-11-27
GT200100015A (es) 2001-10-19
CA2397960A1 (fr) 2001-08-02
UY26550A1 (es) 2001-08-27
PA8510601A1 (es) 2002-08-26
EA004862B1 (ru) 2004-08-26
DK1259474T3 (da) 2009-07-20
PL357076A1 (en) 2004-07-12
ATE431326T1 (de) 2009-05-15
MXPA02007223A (es) 2002-11-29
HUP0204422A2 (en) 2003-05-28
HUP0204422A3 (en) 2003-08-28
NO20023526L (no) 2002-08-27
NZ519550A (en) 2003-11-28
CN1395555A (zh) 2003-02-05
ES2324281T3 (es) 2009-08-04
EP1259474B1 (fr) 2009-05-13
DE60138686D1 (de) 2009-06-25
IL150541A0 (en) 2003-02-12
SV2002000290A (es) 2002-07-16
KR20020073182A (ko) 2002-09-19
CA2397960C (fr) 2008-09-09
GEP20053428B (en) 2005-01-25
AP2002002587A0 (en) 2002-09-30
OA12166A (en) 2003-11-07
BG106851A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DK0817770T3 (da) Nonpeptider som tachykininantagonister
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
NO951761D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
FIU20060389U0 (fi) Luusairauksien hoito
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
MA26951A1 (fr) Derives de pyrazole pour le traitement de maladies virales
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
NO964155D0 (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
ATE323680T1 (de) 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
EP1126850A4 (fr) Traitement des affections de la retine
EP1429775A4 (fr) Procedes de traitement des maladies pulmonaires
ATE296635T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
EP1058546A4 (fr) Traitement de troubles maculaires et composition appropriee
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk